{'fraction_non_alphanumeric': 0.032873806998939555, 'fraction_numerical': 0.017674089784376106, 'mean_word_length': 5.247240618101546, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The role of hepatoprotective and venotonic treatment in the prevention of recurrence of benign and borderline ovarian tumors after performing conservative organ-sparing operations

The objective: to increase the efficiency of treatment of patients with benign (DEOA) and borderline (PEOI) epithelial ovarian tumors after performing organ-sparing operations based on the appointment of a comprehensive anti-relapse therapy. Materials and methods. A clinical examination of 246 patients was conducted. The retrospective group consisted of 112 patients with DEOI and PES. The retrospective group was divided into two subgroups: І subgroup - 85 (75.9%) patients with DEEA; The second subgroup – 27 (24.1%) patients with PED. The prospective group included 60 patients with EOJ, of whom 30 women (subgroup III) were diagnosed with DEWI, and the remaining 30 women (subgroup IV) had PEOI. All women in the prospective group received a course of complex anti-relapse therapy with the inclusion of a non-hormonal modulator of estrogen metabolism, hepatoprotector and venotonics after the conservative surgical treatment was performed. The control group included 64 patients with DEOA and PEDO who were given conservative surgical treatment without prescribing a comprehensive anti-relapse therapy in the future. Used clinical, ultrasonographic with Doppler, histopathological, immunohistochemical studies. Results. During the study of concomitant somatic pathology, it was found that the pathology of the pancreato-hepatobiliary system and venous disease was significantly more often diagnosed in patients with PEOI than DEOA (p<0.05). The purpose of a complex anti-relapse therapy, which includes the non-hormonal estrogen metabolism modulator Quinol (1 capsule twice a day) for 6 months with a repeated course of six months, hepatoprotector Hepanex (1 capsule twice a day) and Pentaven venotonik (1 each) a tablet per day) for 1 month with a repetition of the course 2 times a year for the entire observation period, allowed to reduce the relapse of the DEWD from 13.5% to 3.3%, and PESI – from 29.6% to 10% within three years follow-up assessment of the reproductive health of patients. Conclusion. To optimize the management of patients with DEOA and PEOA after performing conservative surgical treatment, it is recommended to conduct a comprehensive anti-relapse therapy, which includes the use of a non-hormonal modulator of Quinol estrogen metabolism (1 capsule twice a day) for 6 months, repeating the course in six months, hepatoprotector Hepanex (1 capsule twice a day) and Pentavenic venotonics (1 tablet per day) for 1 month with a repetition of the course 2 times a year for 3 years. Key words: benign and borderline ovarian tumors, conservative surgical treatment, estrogen metabolism modulator, hepatoprotector, venotonic.